Rituximab in IgG4-RD: A Phase 1-2 Trial

Summary

The primary objective of this study is to evaluate the safety and effectiveness of rituximab in IgG4-RD.

Timeline

Start

2012-04

Primary completion

2014-01

Completion

2015-01

Outcome

Met primary endpoint

paper The primary outcome was achieved by 23 participants (77%). PMID 25667206 ↗

Publications

• Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, Deshpande V, Smyrk TC, Chari S, Stone JH. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis. 2015 Jun;74(6):1171-7. doi: 10.1136/annrheumdis-2014-206605. Epub 2015 Feb 9.

Drugs

Indications